Century Therapeutics, Inc.
Century Therapeutics is a biotechnology company developing allogeneic pluripotent stem cell therapies designed to treat autoimmune diseases, including type 1 diabetes, and cancer. The company leverages induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Century Therapeutics, Inc. does
In the company’s own words
Century Therapeutics is a biotechnology company developing allogeneic pluripotent stem cell therapies designed to treat autoimmune diseases, including type 1 diabetes, and cancer. The company leverages induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and differentiate into any cell type, enabling virtually unlimited genetic editing, consistent reproducibility, and scalable manufacturing. This approach contrasts with autologous therapies that rely on patient-specific cells, as Century's "off-the-shelf" therapies are derived from healthy donors and engineered cell lines, manufactured in advance and stored for immediate use.
Century's comprehensive platform integrates industry-leading iPSC and differentiation expertise, CRISPR-mediated precision gene editing, proprietary Allo-Evasion technology intended to prevent immune rejection and enable repeat dosing, and cutting-edge manufacturing capabilities. The company can generate multiple mature functional cell types, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alpha-beta T cells, and iPSC-derived natural killer cells, enabling optimal matching of cell characteristics to specific disease indications.
The company's lead product candidate, CNTY-813, is an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 technology for type 1 diabetes treatment. CNTY-308 is a CD19-targeted CD4+/CD8+ CAR-iT cell therapy for B-cell-mediated diseases, while CNTY-101 is a CAR-iNK cell therapy currently being evaluated in the CARAMEL Phase 1/2 investigator-sponsored trial for B-cell-mediated autoimmune diseases including systemic lupus erythematosus and idiopathic inflammatory myopathy.
Century operates a 53,000 square foot cell therapy manufacturing facility in Branchburg, New Jersey, operational since 2022, designed as a flexible multi-product facility capable of producing multiple cell types. The company maintains licensing agreements with Fujifilm Cellular Dynamics, Inc. for iPSC differentiation and reprogramming technology. Century is classified as a smaller reporting company and emerging growth company, with operations focused on research, development, and clinical advancement of its iPSC-derived therapeutic candidates.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1850119
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Century Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Century Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Century Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Century Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Century Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”